Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: Effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors

Journal of the American College of Cardiology

Volumn 32, Issue 7, 1998, Pages 1962-1968

  Sayer, Jeremy W ^a   Gutteridge, Charles ^a   Syndercombe Court, Denise ^a   Wilkinson, Paul ^a   Timmis, Adam D ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; QUINAPRIL; TISSUE PLASMINOGEN ACTIVATOR;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFECT; HEART RATE VARIABILITY; HUMAN; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CIRCADIAN RHYTHM; CORONARY DISEASE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; TETRAHYDROISOQUINOLINES;

EID: 0032406035     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00481-1     Document Type: Article

References (35)

1. Turton M.B., Deegan T. Circadian variation of plasma catecholamines, cortisol and immunoreactive insulin concentrations in supine subjects. Clin Chem Acta. 55:1974;389-397.
2. Deedwania P.C., Nelson J.R. Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring. Circulation. 82:1990;1296-1304.
3. Marchant B., Stevenson R., Vaishnav S., Wilkinson P., Ranjadayalan K., Timmis A.D. Influence of the autonomic nervous system on circadian patterns of myocardial ischaemia comparison of stable angina with the early post-infarction period . Br Heart J. 71:1994;329-333.
4. Hjalmarson A., Gilpin E.A., Nicod P., et al. Differing circadian patterns of symptom onset in subgroups of patients with acute myocardial infarction. Circulation. 80:1989;267-275.
5. Sayer J.W., Wilkinson P., Ranjadayalan K., Ray S., Marchant B., Timmis A.D. Attenuation or absence of circadian and seasonal rhythms of acute myocardial infarction. Heart. 77:1997;325-329.
6. Tanaka T., Fujita M., Fudo T., Tamaki S., Nohara R., Sasayama S. Modification of the circadian variation of symptom onset of acute myocardial infarction in diabetes mellitus. Coronary Artery Dis. 6:1995;241-244.
7. Fava S., Azzopardi J., Muscat H.A., French F.F. Absence of circadian variation in the onset of acute myocardial infarction in diabetic subjects. Br Heart J. 74:1995;370-372.
8. Fearnley G.R., Balmforth G., Fearnley E. Evidence of a diurnal fibrinolytic rhythm; with a simple method of measuring fibrinolysis. Clin Sci. 16:1957;645-650.
9. Grimaudo V., Hauert J., Bachmann F., Kruithof E.K.O. Diurnal variation in the fibrinolytic system. Thomb Haemost. 59:1988;495-499.
10. Kluft C., Verheijen J.H., Rijken D.C., Chang G.T.G., Jie A.F.H., Onkelinx C. Diurnal fluctuations in the activity of the fast acting t-PA inhibitor. Davidson J.F., Donati M.B., Coccheri S. Progress in Fibrinolysis. Vol. 7:1985;117-119 Churchill Livingstone, Edinburgh.
11. Andreotti F., Davies G.J., Hackett D.R., et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol. 62:1988;635-637.
12. Angleton P., Chandler W.L., Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 79:1989;101-106.
13. Bridges A.B., McLaren M., Scott N.A., Pringle T.H., McNeill G.P., Belch J.J.F. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. Br Heart J. 69:1993;121-124.
14. Kapiotis S., Jilma B., Quehenberger P., Ruzicka K., Handler S., Speiser W. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1 + 2, and plasmin-plasmin inhibitor complex. Circulation. 96:1997;19-21.
15. Ridker P.M., Gaboury C.L., Conlin P.R., Seely E.W., Williams G.H., Vaughan D.E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation. 87:1993;1969-1973.
16. Wright R.A., Flapan A.D., Alberti K.G., Ludlam C.A., Fox K.A. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol. 24:1994;67-73.
17. Kaplan K.L., Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood. 57:1981;199-202.
18. Armitage P., Berry G. Statistical Methods in Medical Research. 1994;329-332 Blackwell, Oxford.
19. Pagini M., Mazzuero G., Ferrari A., et al. Sympathovagal interaction during mental stress. A study using spectral analysis of heart rate variability in healthy control subjects and patients with a prior myocardial infarction. Circulation. 83:(suppl II):1991;43-51.
20. Perneger T.V. What's wrong with Bonferroni adjustments. Brit Med J. 316:1988;1236-1238.
21. Savitz D.A., Olshan A.F. Multiple comparisons and related issues in the interpretation of epidemiologic data. Am J Epidemiol. 142:1995;904-908.
22. Thompson J.R. Invited commentary: re: "multiple comparisons and related issues in the interpretation of epidemiologic data" Am J Epidemiol. 147:1998;801-806.
23. de Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J. 71:1994;504-507.
24. Schwartz J.S., Baran K.W., Bache B.S. Effect of stenosis on exercise-induced dilation of large coronary arteries. Am Heart J. 110:1990;520-524.
25. Tousoulis D., Tentolouris C., Crake T., Toutouzas P., Davies G. Basal and flow-mediated nitric oxide production by atheromatous arteries. J Am Coll Cardiol. 29:1997;1256-1262.
26. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation. 96:1997;442-447.
27. Hamdan A.D., Quist W.C., Gagne J.B., Feener E.P. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation. 93:1996;1073-1078.
28. Lonn E.M., Yusuf S., Prabhat J., et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069.
29. Mancini G.B.J., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 94:1996;258-265.
30. James I.M., Dickenson E.J., Burgoyne W., et al. Treatment of hypertension with captopril preservation of regional blood flow and reduced platelet aggregation . J Hum Hypertens. 2:1988;21-25.
31. Someya N., Morotomi Y., Kodama K., et al. Suppressive effects of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol. 6:1984;840-883.
32. Levine S.P., Towell B.L., Suarez A.M., Knieriem L.K., Harris M.M., George J.N. Platelet activation and secretion associated with emotional stress. Circulation. 71:1985;1129-1134.
33. Larsson P.T., Wallen N.H., Martinsson A., Egberg N., Hjemdahl P. Significance of platelet beta-adrenoreceptors for platelet responses in vivo and in vitro. Throm Haemost. 68:1992;687-693.
34. Catalano M., Russo U., Belletti S., et al. Beta-TG and plasma catecholamine levels after sympathetic stimuli in hypertensives and patients with peripheral vascular disease. Thromb Haemost. 63:1990;383-385.
35. Ding Y.A., Chou T.C., Lin K.C. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension. J Hum Hypertens. 8:1994;273-278.